🚨 New in NEJM 🫁: The IMPALA-2 trial shows that inhaled molgramostim significantly improves gas exchange, quality of life, and exercise capacity in patients with autoimmune pulmonary alveolar proteinosis (aPAP)—a rare disease driven by GM-CSF autoantibodies.
💨 Say goodbye to whole-lung lavage—this is a bench-to-bedside success story 30 years in the making.
🔬 From GM-CSF knockout mice ➡️ inhaled cytokine therapy ➡️ regulatory-grade RCT.
🏆 A major win for translational respiratory medicine.
#Pulmonology #RareDiseases #GMCSF #AutoimmuneDisease #Molgramostim #PrecisionMedicine #TranslationalResearch #NEJM #aPAP #LungHealth #RCT #CytokineTherapy #BenchToBedside #InhaledTherapy 🧬🫁💊
